Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100mg, GSK2190915 300mg, Montelukast 10mg or Placebo Tablets Once Daily or Salmeterol 50mcg Inhalation Powder Twice Daily to Fluticasone Propionate 100mcg Inhalation Powder Twice Daily in Uncontrolled Asthmatic Subjects ≥ 12 Years of Age
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of adding GSK2190915 100mg, GSK2190915 300mg or placebo tablets administered once daily to fluticasone propionate 100mcg inhalation administered twice daily in uncontrolled asthmatic subjects \> or = 12 years of age over the course of 6 weeks treatment.

The secondary objectives are to undertake an exploratory analysis of the efficacy and safety of adding montelukast 10mg administered once daily or salmeterol 50mcg administered twice daily to fluticasone propionate 100mcg inhalation administered twice daily and to investigate the pharmacokinetics and pharmacodynamics of GSK2190915 in uncontrolled asthmatic subjects \> or = 12 years of age over the course of 6 weeks treatment.


Options:
A: Arm Label: Sequence #1; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #2; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #3; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #4; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #5; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #6; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Intervention Type: DRUG; Name: fluticasone propionate + montelukast; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate + salmeterol; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6
B: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
C: Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Singular pill; Type: EXPERIMENTAL; Interventions: Drug: singular | Intervention Type: DRUG; Name: singular; Assigned to Arm(s): Singular pill | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo pill
D: Arm Label: FP 100mcg BID plus GSK2190915 100mg QD (AM); Type: EXPERIMENTAL; Interventions: Drug: FP 100, Drug: GSK2190915 100 | Arm Label: FP 100mcg BID plus GSK2190915 300mg QD (AM); Type: EXPERIMENTAL; Interventions: Drug: FP 100, Drug: GSK2190915 300 | Arm Label: FP 100mcg BID plus montelukast 10mg QD (PM); Type: ACTIVE_COMPARATOR; Interventions: Drug: FP 100, Drug: montelukast | Arm Label: FP 100mcg BID plus placebo BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: FP 100, Drug: placebo | Arm Label: FP/SAL 100/50mcg BID plus placebo BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo, Drug: FP/SAL 100/50 | Intervention Type: DRUG; Name: FP 100; Assigned to Arm(s): FP 100mcg BID plus GSK2190915 100mg QD (AM), FP 100mcg BID plus GSK2190915 300mg QD (AM), FP 100mcg BID plus montelukast 10mg QD (PM), FP 100mcg BID plus placebo BID | Intervention Type: DRUG; Name: GSK2190915 100; Assigned to Arm(s): FP 100mcg BID plus GSK2190915 100mg QD (AM) | Intervention Type: DRUG; Name: GSK2190915 300; Assigned to Arm(s): FP 100mcg BID plus GSK2190915 300mg QD (AM) | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): FP 100mcg BID plus montelukast 10mg QD (PM) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): FP 100mcg BID plus placebo BID, FP/SAL 100/50mcg BID plus placebo BID | Intervention Type: DRUG; Name: FP/SAL 100/50; Assigned to Arm(s): FP/SAL 100/50mcg BID plus placebo BID

Answer: D